Healthcare intellectual property commercialisation company NetScientific announced on Monday that its portfolio company Wanda Health is expanding into orthopedics through a new partnership with HRS Home Health.
The AIM-traded firm said Wanda's predictive analytics and artificial intelligence solutions already provided remote management solutions for chronic conditions in heart and respiratory health.

It explained that the partnership with HRS, a Wanda client, brought Wanda's capabilities to the field of orthopedics, with initial pilot studies demonstrating a decrease in the length of time patients were required to remain in hospital through the use of Wanda's technology.

HRS would use Wanda telehealth and predictive analytics products to provide real-time data and informatics to orthopedic surgeons and their clinical teams.

NetScientific said HRS Home Health partnered with orthopedic surgeons in Omaha, Nebraska to collect metrics in patients' homes, which tracked patient outcomes post-surgery.

HRS reportedly identified gaps in clinical information that were not being reported to the surgeons and their clinical teams during the critical time frame from three to 14 days of post-operative care.

To improve patient outcomes, five key metrics were identified for remote telehealth data collection to assist with real time clinical oversight - knee flexion, knee extension, pain with activity, knee circumference, and quadriceps strength.

Initial pilot results demonstrated a decrease in cost per case of 18% compared to cases not involved in the pilot.

NetScientific said initial pilot cases showed a decrease in length of stay from 19.4 days to 11.5 days.

Those patients achieved desired outcomes 41% quicker than prior to the pilot.

The integration of Wanda's technology with HRS care interventions had also decreased readmissions, LOS and cost of care, NetScientific claimed.

"We are delighted to announce that Wanda is expanding its analytical focus to orthopedics, which demonstrates the flexibility and potential of the technology," said Wanda chairman and NetScientific CEO Francois Martelet.

"In particular, we are pleased that the initial pilot cases demonstrate a decrease in length of stay from 19.4 days to 11.5 days, achieving desired outcomes for patients 41% quicker when using Wanda technology."

Related share prices
NetScientific (NSCI) share price